Loading...
A subset of chronic myeloid leukemia (CML) patients treated with imatinib or the second-generation tyrosine kinase inhibitors (TKIs) nilotinib or dasatinib achieve ongoing molecular remission, as assessed by reverse transcription quantitative polymerase chain reaction.
Investigators have now conducted a multicenter, observational study to test whether CML patients could discontinue nilotinib or dasatinib after at least 3 years of receiving therapy and at least 2 years of achieving molecular response. A total of 60 patients who had been followed for at least 12 months after discontinuation were analyzed. After discontinuation, molecular monitoring was performed monthly for the first year, every 2 to 3 months in year 2, and then every 3 to 6 m…